ACTISITE (tetracycline hydrochloride) by Pfizer is clinical pharmacology tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. First approved in 1994.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
ACTISITE is a tetracycline hydrochloride fiber formulation delivered as an extended-release periodontal insert for localized treatment of periodontal disease. It works by inhibiting bacterial protein synthesis via binding to the 30S ribosomal subunit, exerting bacteriostatic activity against a broad spectrum of gram-positive and gram-negative organisms including Propionibacterium acnes and periodontal pathogens. The product targets patients with active periodontal pockets requiring adjunctive antimicrobial therapy.
Product is in late-stage life cycle with moderate competitive pressure (30), indicating defensive marketing and niche positioning rather than growth-phase expansion opportunities.
CLINICAL PHARMACOLOGY Tetracyclines are readily absorbed and are bound to plasma protein in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Microbiology Tetracyclines are primarily…
Worked on ACTISITE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ACTISITE offers limited near-term career growth; the product is in life-cycle management mode with declining innovation opportunity. Roles tend to focus on defending market share, optimizing reimbursement, and managing transition planning rather than expansion or new indication development.